Corcept Therapeutics Incorporated (CORT)
NASDAQ: CORT · Real-Time Price · USD
110.29
-4.57 (-3.98%)
At close: Sep 18, 2026, 4:00 PM EDT
111.00
+0.71 (0.64%)
After-hours: Sep 18, 2026, 7:56 PM EDT
Corcept Therapeutics Stock Forecast
Stock Price Forecast
According to 5 analysts polled by S&P Global, Corcept Therapeutics stock has a consensus rating of "Buy" and an average price target of $141. The average 1-year stock price forecast is 27.84% higher than the current stock price, while the lowest is $50 (-54.66%) and the highest is $165 (+49.61%).
Price Target: $141 (+27.84%)
Analyst Consensus: Buy
Price Target
ChartAnalyst Ratings
The average analyst rating for Corcept Therapeutics stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Apr '26 | May '26 | Jun '26 | Jul '26 | Aug '26 | Sep '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 4 | 4 | 2 | 3 | 3 |
| Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Hold | 2 | 1 | 1 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 1 | 1 | 1 |
| Total | 6 | 6 | 6 | 4 | 5 | 5 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| H.C. Wainwright | H.C. Wainwright | Buy Maintains $165 | Buy | Maintains | $165 | +49.61% | Sep 18, 2026 |
| Piper Sandler | Piper Sandler | Buy Reiterates $165 | Buy | Reiterates | $165 | +49.61% | Aug 21, 2026 |
| Truist Financial | Truist Financial | Buy Initiates $50 → $164 | Buy | Initiates | $50 → $164 | +48.70% | Aug 18, 2026 |
| Canaccord Genuity | Canaccord Genuity | Buy Reiterates $161 | Buy | Reiterates | $161 | +45.98% | Aug 13, 2026 |
| Wolfe Research | Wolfe Research | Sell Maintains $50 | Sell | Maintains | $50 | -54.66% | Jul 30, 2026 |
Financial Forecast
Revenue This Year
1.15B
from 761.41M
Increased by 50.53%
Revenue Next Year
1.70B
from 1.15B
Increased by 48.75%
EPS This Year
2.15
from 0.82
Increased by 162.20%
EPS Next Year
4.40
from 2.15
Increased by 104.77%
EPS and Forward PE are based on non-GAAP adjusted numbers.